Coronary vasomotion dysfunction after everolimus-eluting stent implantation

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomedical Engineering

Background:

• Drug-eluting stents (DES) are widely used to prevent coronary artery restenosis.
• First-generation DES, including those with sirolimus, paclitaxel, and zotarolimus, have been associated with paradoxical "in-segment" coronary vasoconstriction.
• The underlying mechanisms of this phenomenon remain incompletely understood.

Observation:

• A novel case of coronary vasoconstriction was observed following the implantation of everolimus-eluting stents (EES).
• This represents the first documented instance of EES-induced coronary vasoconstriction.
• The vasoconstriction occurred in the "in-segment" region of the coronary artery.

Findings:

• Everolimus-eluting stents (EES), a newer generation DES, can also induce coronary vasoconstriction.
• This finding expands the spectrum of DES known to cause this adverse vascular response.
• The study provides crucial clinical evidence of EES-associated coronary vasoconstriction.

Implications:

• Clinicians should be aware of the potential for EES to cause coronary vasoconstriction.
• Further research is warranted to elucidate the mechanisms behind EES-induced vasoconstriction.
• This may inform the development of future stent designs with reduced risk of coronary vasoconstriction.